Trademark: 77388974
Status Date
Tuesday, January 19, 2010
Filing Date
Tuesday, February 5, 2008
Abandoned Date
Thursday, December 24, 2009
42 Advisory services relating to diagnostic preparations and products, namely, consulting and advisory services relating to prediction of response of individuals to pharmaceutical products and treatments for diseases and disorders of the central nervous system, consulting and advisory services relating to prediction of response of individuals to pharmaceutical products and treatments for psychiatric disorders, consulting and advisory services relating to the development, testing and efficacy, of pharmaceutical preparations and products for the treatment of diseases and disorders of the central nervous system, consulting and advisory services relating to the development, testing and efficacy, of pharmaceutical preparations and products for the treatment of Psychiatric diseases and disorders, and consulting and advisory services relating to the provision of goods containing reagents for use in the collection and testing of DNA, RNA and bodily tissues; advisory services relating to diagnostic apparatus and diagnostic instruments, namely, consulting and advisory services relating to prediction of response of individuals to pharmaceutical products and treatments for diseases and disorders of the central nervous system, consulting and advisory services relating to prediction of response of individuals to pharmaceutical products and treatments for psychiatric disorders, relating to apparatus and instruments used in the prediction of the response of individuals to pharmaceutical products and treatment for diseases and disorders of the central nervous system, relating to apparatus and instruments used in the prediction of the response of individuals to pharmaceutical products and treatment for psychiatric diseases and disorders, consulting and advisory services relating to the development, testing and efficacy, of apparatus and diagnostic instruments for the treatment of diseases and disorders of the central nervous system, consulting and advisory services relating to the development, testing and efficacy, of pharmaceutical preparations and products for the treatment of psychiatric diseases and disorders, in connection with assays or assay kits for use in the collection and testing of DNA, RNA and bodily tissues, and in connection with assay kits (which may contain reagents) for use in the collection of DNA, RNA and bodily tissues; design and control of pharmacogenetic diagnostic tests for prediction of response of individuals to pharmaceutical products and treatments, for disorders of the central nervous system; design and control of pharmacogenetic diagnostic tests for prediction of response of individuals to pharmaceutical products and treatments, for psychiatric disorders; design and control of pharmacogenetic diagnostic tests for disorders and diseases of the central nervous system; design and control of pharmacogenetic diagnostic tests for psychiatric diseases and disorders; design and control of pharmacogenetic tests, including the devising, compiling and testing of algorithms and mathematical systems for predicting response to a pharmaceutical product based on individual genetic profile; scientific research related to pharmacogenetics; research and advisory services relating to pharmaceuticals
44 Medical diagnostic services; diagnostic testing relating to the human body, namely, diagnostic testing and analysis of samples, in order to predict response of individuals to pharmaceutical products and treatments for disorders of the central nervous system, diagnostic testing and analysis of samples in order to predict response of individuals to pharmaceutical products and treatments for psychiatric disorders, diagnostic testing and analysis of samples in order to confirm diagnosis of diseases and disorders of the central nervous system, and diagnostic testing and analysis of samples in order to confirm diagnosis of Psychiatric diseases and disorders; clinical services, namely, the analysis of samples of DNA, RNA and bodily tissues in order to prescribe the pharmaceutical product or treatment best suited to the patient (i.e. the pharmaceutical product likely to have the most beneficial effect and/or the one with fewest or least severe side effects), the taking of samples of bodily tissues for analysis in connection with the prescription of pharmaceuticals, or other medical treatment, and medical and scientific research in the nature of conducting clinical trials; compilation of medical reports, relating to prediction of response of individuals to pharmaceutical products and treatments for disorders of the central nervous system; compilation of medical reports, relating to confirmation of diagnosis of diseases and disorders of the body, and prescription of most efficient and efficacious pharmaceutical product or method for treatment thereof; compilation of medical reports, namely, a resource of phenotypic and genotypic data relating to diseases and disorders of the central nervous system and psychiatric diseases and disorders; conducting of medical examinations for diagnosis of treatments; testing and profiling for medical purposes; computer aided diagnostic testing services relating to the human body
Jan 19, 2010
Abandonment Notice Mailed - Failure To Respond
Jan 19, 2010
Abandonment - Failure To Respond Or Late Response
Jun 23, 2009
Notification Of Inquiry As To Suspension E-Mailed
Jun 23, 2009
Inquiry To Suspension E-Mailed
Jun 23, 2009
Suspension Inquiry Written
Jun 23, 2009
Lie Checked Susp - To Atty For Action
Dec 23, 2008
Notification Of Letter Of Suspension E-Mailed
Dec 23, 2008
Letter Of Suspension E-Mailed
Dec 23, 2008
Suspension Letter Written
Dec 23, 2008
Examiner's Amendment Entered
Dec 23, 2008
Notification Of Examiners Amendment E-Mailed
Dec 23, 2008
Examiners Amendment E-Mailed
Dec 23, 2008
Examiners Amendment -Written
Dec 11, 2008
Teas/Email Correspondence Entered
Dec 11, 2008
Correspondence Received In Law Office
Dec 9, 2008
Teas Response To Office Action Received
Nov 24, 2008
Notification Of Non-Final Action E-Mailed
Nov 24, 2008
Non-Final Action E-Mailed
Nov 24, 2008
Non-Final Action Written
Nov 7, 2008
Teas/Email Correspondence Entered
Nov 7, 2008
Correspondence Received In Law Office
Nov 5, 2008
Teas Response To Office Action Received
Jun 6, 2008
Teas Change Of Correspondence Received
May 5, 2008
Notification Of Non-Final Action E-Mailed
May 5, 2008
Non-Final Action E-Mailed
May 5, 2008
Non-Final Action Written
Apr 30, 2008
Assigned To Examiner
Apr 29, 2008
Assigned To Examiner
Mar 19, 2008
Applicant Amendment Prior To Examination - Entered
Mar 13, 2008
Assigned To Lie
Feb 15, 2008
Teas Voluntary Amendment Received
Feb 9, 2008
Notice Of Pseudo Mark Mailed
Feb 8, 2008
New Application Entered In Tram
Trademark Alertz updated from USPTO on 2030-01-24
